[{"arm_notes": "", "treatment_id": null, "treatment_name": "Group name:OT-101 Type of group;1 N\u00b0 of participants:48 Intervention(s) description:Name of the IMP: OT 101 (Trabedersen; TGF-β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide).Dose and dosage regimen:Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days.Formulation: Lyophilized powder.Group name:Placebo Type of group;2 N\u00b0 of participants:24 Intervention(s) description:Dose and dosage regimen: Days 1 to 7 daily i.v. infusion for 7 continuous days. Formulation: Saline solution", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1305, "treatment_name": "Trabedersen", "treatment_type": "Others pharmacological treatment", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]